I’ve been staying away from the board (other than to read

New Post Public Reply Private Reply Replies (2) Message Board
homerbedloe
379
I’ve been staying away from the board (other than to read highly recommended posts) because there just isn’t much to say positive or negative since in fact, we do not actually know what is going on behind the scenes – everyone here is speculating. But I’m getting a sense that people are expecting big things because of the back to back CC’s this week. That makes no sense to me at all at this point.

I have come to believe that nothing, and I mean NOTHING, is going to come out of the CCs that materially affects the pps. Joe could say it is now believed that AE37 cures cancer and the pps would not change. I think there are only two things that will affect pps for these two companies, and one probably won’t affect the other.

The NGIO spinout will create a value for NGIO shares. Hopefully, it will be in the multi-billion range, which will land NGIO at $5/share or above. This will happen, eventually, but nothing in the CC on Thurs will accelerate it. And for what it’s worth, I now believe that even this event will not affect GNBT’s share price. Yes, there will be a huge asset on GNBT’s books (maybe even something that can remove the going concern notice), but that does not mean it will translate to a pps rise. There may be a temporary bump, but it likely won’t be large and it won’t be long term. We saw this with the retirement of 20 million shares of GNBT – nadda, nyet, nothing happened with the pps. So why should an addition to the books make a difference?

What will make a difference? S1 funding? Nope – at least, not directly. Again, I believe there will a small bump in pps with the announcement of any of the S1 registrations, but it won’t last either. What will make a difference is once Joe gets funding, and he can further the subsidiaries to a point they start showing GROWING revenue, THEN we’ll see GNBT’s pps start a sustained upturn.
But that isn’t happening Wed, nor next month or probably throughout the 4th quarter this year. If we receive S1 approval in the next couple of months, I would expect at least another year before the funding can flow through to develop the businesses and start seeing actual revenues. So next year is the earliest I see GNBT’s pps doing anything, and even that might be optimistic.

Does this mean I think Joe isn’t doing all he can to increase value for shareholders? Nope – based on recent PRs, he has truly knitted a silk purse out of a sow’s ear. But it hasn’t and won’t matter - there is something going on behind the OTC scene that holds GNBT share price down. Bad actors, lack of interest or trust, market makers screwing around between themselves for whatever purposes? I don’t know, and it doesn’t make much difference if I did know because there’s nothing I or you can do about it. The news on GNBT has been such that it should rise, but it doesn’t. That is all that matters, and using that history, I’m projecting it to continue until Joe can fund the subsidiaries and they can establish their own worth.

NGIO will be different – it will trade on emotion (hope or fear) once it is uplisted. Sorry to those here that currently don’t have NGIO shares from the dividends; if you only have GNBT shares, you’ll have longer to wait for a payoff. I still think it will come, but it won’t be Wednesday, Thursday, next month or even early next year. If I’m right, you’ll have to make the decision do you want to keep holding for the turnaround, or are there better, more well thought of stocks (CYDY?) that you should be investing in.

My opinion only, mileage will vary.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Updated Category News Views 130

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

Continue Reading
CURE Intl and Thoughtworks Step Into Digital Era

Updated Category News Views 117

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Continue Reading
Jinko Solar Joins B20 Summit: Energy Forefront Focus

Updated Category News Views 105

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 47

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Updated Category News Views 130

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Continue Reading
Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Updated Category News Views 27

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

Continue Reading
LG Innotek Scores Hat Trick with CES Innovation Wins

Updated Category News Views 86

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

Continue Reading
RF MEDICAL Expands into Europe with New CE Certification

Updated Category News Views 62

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

Continue Reading
BD Sets Stage for Investor Day in December 2026

Updated Category News Views 9

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Continue Reading
Centrus Energy Welcomes Nuclear Veteran to Leadership

Updated Category News Views 14

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Continue Reading

Top 5 Most Recently Viewed Articles

RPIA Launches the Innovative RP Alternative Credit Fund

Updated Category News Views 265

Introducing the RP Alternative Credit Opportunities Fund RPIA, a prominent player in the liquid alternatives sector, has just launched the RP Alternative Credit Opportunities Fund (ACOF). This fund is designed for investors seeking a tactical approach within the liquid alternative credit strategy landscape, blending daily liquidity with institutional-grade investment...

Continue Reading
Texas Court Advances Lawsuit for Houston Assistant Fire Chiefs

Updated Category News Views 162

Texas Court of Appeals Rules for Assistant Fire Chiefs The Fourteenth Court of Appeals has recently made a crucial ruling concerning the rights of thirteen Assistant Fire Chiefs in a legal dispute with both the City of Houston and the Houston Professional Fire Fighters' Association. This ruling allows these dedicated professionals, who play a vital role in ensuring the...

Continue Reading
Revolutionary Wireless Charging Device Enhances User Experience

Updated Category News Views 298

Innovative Wireless Charger Unveiled With the rapid evolution of technology, charging solutions are also advancing. A visionary inventor has introduced a groundbreaking device, designed to enhance the way we charge our phones. This device, known as the TACTIC, was conceived with a clear goal in mind: to make charging seamless, even while using the phone. Understanding the...

Continue Reading
Cunningham Bounds Elevates Joseph McGowin to Partner Role

Updated Category News Views 142

Cunningham Bounds Elevates Joseph McGowin to Partner Role Cunningham Bounds is thrilled to announce Joseph McGowin's promotion to Partner. This decision acknowledges his exceptional trial skills and unwavering commitment to representing individuals and families affected by negligence and wrongful conduct. Throughout his career, Joseph has fought tirelessly for his...

Continue Reading
Asetek's Q3 Performance Signals Future Growth Potential

Updated Category News Views 239

Asetek's Latest Financial Results Asetek has reported its financial results for the third quarter of 2025, noting a revenue of $9.8 million. This figure shows a decline compared to the $12.2 million reported in the same quarter of 2024. The company has faced fewer shipments of liquid cooling products, which has significantly affected revenue over these periods. Gross...

Continue Reading